NCT06886425View on ClinicalTrials.gov

Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies

NARecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

June 14, 2026

Study Completion Date

June 14, 2028

Conditions
Myelodysplastic Syndromes (MDS)Leukemia Acute Myeloid - AML
Interventions
OTHER

genetic study

"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"

OTHER

Pharmacokinetic study

"Cure 1: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 3: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 6: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase."

OTHER

Study of phenotypic activity of cytidine deaminase

"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"

Trial Locations (1)

13005

RECRUITING

Hôpital de la Conception, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER